CSRxP COMMENDS ADMINISTRATION FOR CHALLENGING MORE THAN 200 OF BIG PHARMA’S SHAM PATENTS THAT BLOCK COMPETITION AND KEEP DRUG PRICES HIGH

FTC’s Continued Crackdown on Bogus Patents Listed in the Orange Book Will Help Bring More Affordable Alternatives to American Patients More Quickly

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued the following statement on Tuesday on the Federal Trade Commission (FTC) challenging the validity of more than 200 patents on brand name prescription drugs listed in the U.S. Food and Drug Administration (FDA)’s Orange Book.

“CSRxP commends the Administration for continuing the FTC’s crackdown on Big Pharma’s sham patents in the Orange Book that block competition from more affordable alternatives to high-priced brand name drugs,” said CSRxP executive director Lauren Aronson. “By challenging sham patents, building on positive progress to better coordinate among agencies and advancing bipartisan, market-based solutions in Congress to hold Big Pharma accountable for anti-competitive practices, policymakers in Washington can deliver greater competition in the prescription drug marketplace and lower prices for the American people.”

Learn more on Big Pharma’s patent abuse that blocks competition and keeps drug prices high HERE.

Read more on bipartisan, market-based solutions to hold Big Pharma accountable HERE.